



MEDIA RELEASE

QT VASCULAR ANNOUNCES FEDERAL CIRCUIT REVERSAL OF ADVERSE ANGIOSCORE / SPECTRANETICS JUDGEMENT

Highlight:

- In a legal victory for QT Vascular Group and its CEO, the United States Court of Appeals for the Federal Circuit reversed a California district court judgment awarding AngioScore more than US\$20,000,000, and directed the district court to dismiss the State Law Claims

SINGAPORE, 25 July 2016 – QT Vascular Ltd., together with its subsidiaries (the “**Company**” or “**QT Vascular**”, and together with its subsidiaries, the “**Group**”), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease. Further to the Company’s announcements of 29 April 2015, 2 July 2015 and 8 July 2015 and media releases of 4 May 2015, 20 September 2015, 26 November 2015 and 11 February 2016, the Board of Directors of the Company is pleased to provide an update in its ongoing litigation with AngioScore, Inc. (“**AngioScore**”) (now owned by Spectranetics Corporation (NASDAQ: SPNC)).

On 21 July 2016, a unanimous three-judge panel of the United States Court of Appeals for the Federal Circuit (the “**Federal Circuit**”) reversed a district court judgement awarding AngioScore more than US\$20,000,000 in damages based on claims of breach of fiduciary duty, aiding and abetting the breach and unfair competition (the “**State Law Claims**”). The Federal Circuit held that the district court erred as a matter of law when it exercised subject matter jurisdiction over the State Law Claims. Accordingly, the Federal Circuit ordered the district court to dismiss the State Law Claims.

The aforesaid ruling on 21 July 2016 is a second win for the Group at the Federal Circuit this year, and it leaves unchanged the previous positive judgement that Chocolate® PTA does not infringe any of the asserted claims of United States Patent No. 7,691,119 (“**’119 patent**”) and that all asserted claims of the ’119 patent by AngioScore are invalid as obvious over the prior art.

“I am delighted that we won this appeal as it validates the stand taken by the Group since the start of this litigation with AngioScore” stated Dr Eitan Konstantino, PhD, Chief Executive Officer of QT Vascular.

~~ End ~~

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries (“**QT Vascular**” or the “**Group**”), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC (“**TriReme Medical**”), based in Pleasanton, California. TriReme Medical’s range of percutaneous transluminal angioplasty (“**PTA**”) and percutaneous transluminal coronary angioplasty (“**PTCA**”) products include (i) Chocolate[®] PTA Balloon Catheter, (ii) Chocolate[®] PTCA Balloon Catheter, (iii) GliderXtreme[™] PTA Balloon Catheter, (iv) GliderfleX[®] PTA Balloon Catheter and (v) Glider[™] PTCA Balloon Catheter, all of which have the CE mark that allows them to be sold in Europe, and FDA clearance to be sold in the United States. Additionally, the GliderXtreme[™] PTA Balloon Catheter has the regulatory clearance in China and Japan, while the Glider[™] PTCA Balloon Catheter has the regulatory clearance in Japan. These products are sold by the Group’s direct sales team and through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Cardinal Health, Inc.), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group’s drug coated version of the Chocolate[®] PTA Balloon Catheter, Chocolate Touch[®], and the Chocolate[®] PTCA Balloon Catheter, Chocolate Heart[™], have the CE mark that allows them to be sold in Europe.

For more information, please visit the company website at www.qtvvascular.com

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD

Tel: +65 6100 2228

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as “expect”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “plan”, “strategy”, “forecast” and similar expressions or future or conditional verbs such as “if”, “will”, “would”, “should”, “could”, “may” and “might”. These statements reflect the Company’s current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

*This press release has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (“**Sponsor**”), for compliance with the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.